Exit Menu

CIRTM members have expertise in the following fields of research:

      • Thrombo-inflammation and its resolution following ischaemic reperfusion injury in cardiovascular and cerebrovascular diseases
      • Pharmacology and drug safety studies (e.g. non-steroidal anti-inflammatory drugs) in zebrafish; adverse outcome pathway development to predict in vivo drug toxicity
      • Growth factor genes in cancer immune surveillance and autoimmunity; mechanisms of antigen presentation for tumour vaccination
      • Protective endogenous factors (e.g. lung surfactant protein D) as therapeutic targets in asthma and lung infection
      • Innate and adaptive immunity to infectious diseases; vaccine-induced biomarkers of protection against tuberculosis; bacillus Calmette-Guerin (BCG) vaccination and its mechanisms of action; immunometabolism as a vaccine target
      • Molecular epidemiology of tuberculosis and molecular evolution of Mycobacterium tuberculosis
      • The microbiome, microbial ecology and ecosystems.
      • Signalling pathways that control antimicrobial resistance and biofilm formation
      • Pseudomonas aeruginosa and Acinetobacter baumannii pathogenesis
      • Large scale analysis of clinical and genetic determinants for cardiovascular diseases
      • The role of oncogenic transcription factors in the development of neuroblastoma and adenoid cystic carcinoma
      • New cell and gene therapy approaches for monogenic diseases (Friedreich’s ataxia)
      • Roles and therapeutic opportunities involving cilia and centrioles in cancer and ciliopathies
      • Volatile organic compound analysis for non-invasive disease diagnosis and environmental monitoring

Within the Centre, we have a wealth of expertise in many analytic research tools and techniques and, either at our Uxbridge campus or through collaborative links, have access to the following technical resources:

      • In vivo (rodent and larger species e.g. pigs) models of disease such as thrombosis, inflammation, infection, lung allergy, oedema and transplantation
      • Mouse models of human cancers (neuroblastoma and adenoid cystic carcinoma)
      • Zebrafish models of drug safety and mechanisms of action
      • In vivo Galleria mellonella model (infection, microbiome, burn wound, drug discovery/kinetics)
      • Robotic High throughput screening (phenotype screening, drug discovery, library preparation, colony picking)
      • Gene synthesis; cDNA cloning; recombinant protein expression in E. coli, Pichia pastoris, baculovirus, Drosophila S2 cells and mammalian cell lines; Crispr/Cas9 technology
      • High throughput sequencing; microarray; proteomics; epigenomics; ELISA; immunohistochemistry; multiparameter flow cytometry; multiplex bead array assays
      • Intra-vital and confocal intravital microscopy; magnetic resonance imaging; positron emission tomography; single photon emission tomography and in vivo imaging systems
      • Confocal analysis of mitochondrial dynamics and function
      • In vitro models of human innate and adaptive immune responses, mycobacterial growth inhibition assays
      • Bioinformatic and statistical analysis of large datasets; genome-wide association studies; genetic risk scores; machine learning
      • Selected ion flow tube mass spectrometry for volatile compound and trace gas analysis